In a Legal Backgrounder released by the USA-based Washington Legal Foundation, entitled, WTO Ruling on Biotech Foods Addresses "Precautionary Principle," international business and trade expert Lawrence Kogan of the non-profit Institute for Trade, Standards and Sustainable Development (ITSSD), argues that the recent World Trade Organization ruling represents a blow to the proponents of the "Precautionary Principle" in Europe and a victory for "best available science" in the regulatory process.
The WLF says that the Precautionary Principle eschews science-based "risk" assessments and an evaluation of the economic benefits and costs of regulation. Instead, it favors the enactment of overly strict and burdensome environmental, health and safety rules based on unfounded activist fears of hypothetical hazards, for the purpose of eliminating every possible future risk from economic conduct, it explains.
The WTO issued its ruling on the complaint by the USA, Argentina, and Canada, on September 29, and much to the chagrin of environmental groups, European Commission accepted it as final, on November 22. As Mr Kogan relates, the WTO panel found that European Union restrictions on approval of genetically-enhanced seeds and food products violated provisions of the WTO Sanitary and Phytosanitary Agreement. The EU's anti-biotechnology policies, the panel found, were based more on political considerations than scientific evidence.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze